Our data consistently revealed that inhibition of PDE4B by rolipram could rescue the tumor-promoting effects from PDE4B overexpression on cell invasion and EMT, suggesting that rolipram would be a promising UBC pharmacological inhibitor targeting PDE4B. The gene discussed is UBC; the disease is neoplasm.